Skip to main content

Table 4 Associations between COX H-score and ovarian cancer survival by tumor type, the Vanderbilt TROC

From: Differential cyclooxygenase expression levels and survival associations in type I and type II ovarian tumors

  Disease-free survival Overall survival
HR (95% CI), P-value P-interaction HR (95% CI), P-value P-interaction
COX-1 / PTGS1
 Among Type I Cases (N = 65)
  N cases / eventsa 28 / 3 vs 21 / 5   39 / 14 vs 26 / 8  
  Unadjusted 2.20 (0.52–9.20) 0.282 0.537 0.71 (0.29–1.70) 0.435 0.210
  Adjustedb 2.88 (0.55–15.04) 0.209 0.56 (0.23–1.38) 0.210
 Among Type II Cases (N = 125)
  N cases / eventsa 32 / 23 vs 37 / 26   56 / 43 vs 69 / 55  
  Unadjusted 1.32 (0.75–2.31) 0.339   1.10 (0.74–1.64) 0.636  
  Adjustedb 1.34 (0.76–2.37) 0.313   1.07 (0.72–1.60) 0.740  
COX-2 / PTGS2
 Among Type I Cases (N = 65)
  N cases / eventsa 10 / 2 vs 39 / 6   19 / 11 vs 46 / 11  
  Unadjusted 0.90 (0.18–4.52) 0.899 0.181 0.38 (0.16–0.88) 0.023 0.051
  Adjustedb 0.51 (0.08–3.40) 0.490 0.49 (0.20–1.15) 0.102
 Among Type II Cases (N = 125)
  N cases / eventsa 36 / 27 vs 33 / 22   76 / 61 vs 49 / 37  
  Unadjusted 1.07 (0.60–1.88) 0.829   0.84 (0.56–1.27) 0.413  
  Adjustedb 1.93 (1.06–3.53) 0.033   1.08 (0.71–1.63) 0.723  
  1. aN cases / N events, reference vs high COX, measured by H-score, dichotomized at the median
  2. bAdjusted for age at diagnosis (continuous) and stage (early, late) Bold values denote signficant associations; column percentages may not sum to 100% due to rounding error